1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Celyad Oncology SA
  6. News
  7. Summary
    CYAD   BE0974260896


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Celyad Oncology SA Announces Program Update and Anticipated Milestones for 2022

01/12/2022 | 06:07am EDT

Celyad Oncology SA announced a 2021 year-end review and provided an outlook for 2022. 2021 Business Highlights: Dosed first patient in KEYNOTE-B79 Phase 1b trial (NCT04991948), which will evaluate the TCR Inhibitory Molecule (TIM)-based allogeneic NKG2D CAR T cell investigational therapy CYAD-101 with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with refractory metastatic colorectal cancer (mCRC) with microsatellite stable (MSS) /mismatch-repair proficient disease. Data from the dose-escalation segment of the IMMUNICY-1 Phase 1 trial (NCT04613557) evaluating the allogeneic shRNA-based anti-BCMA CAR T candidate CYAD-211 in patients with relapsed or refractory multiple myeloma (r/r MM) showed evidence of clinical activity with a good tolerability profile including no evidence of Graft versus Host Disease (GvHD). In addition, all patients in trial had detectable CYAD-211 cells in the peripheral blood. Research & Development Day in July showcased the Company’s current pipeline of allogeneic CAR T programs and shRNA-based preclinical concepts while also introducing CYAD-203 – an allogeneic shRNA-based interleukin-18 (IL-18)-armored NKG2D CAR T candidate. Presented clinical results from the CYCLE-1 Phase 1 trial (NCT04167696) evaluating the next-generation, autologous NKG2D receptor CAR T candidate CYAD-02. Data from the study showed that a single shRNA can target two independent genes (MICA/MICB) to enhance the phenotype of the CAR T cells – a differentiated approach among currently available gene-expression control technologies. Bolstered balance sheet with $32.5 million private placement with an affiliate of Fortress Investment Group. The Company believes its existing cash and cash equivalents combined with access to the equity purchase agreement established with Lincoln Park Capital Fund, LLC should be sufficient to fund operating expenses and capital expenditure requirements into the first half of 2023. Program Update and Anticipated Milestones for 2022: Following the dose-escalation segment of the IMMUNICY-1 Phase 1 trial for CYAD-211, the next segment of the study will evaluate enhanced lymphodepleting regimens with the aim to improve cell persistence and potentially maximize the clinical benefit of the anti-BCMA CAR T candidate. The IMMUNICY-1 protocol also allows for CYAD-211 redosing in certain patients. Enrollment in the cohorts evaluating enhanced lymphodepletion is ongoing and additional data from the CYAD-211 IMMUNICY-1 trial are expected in mid-2022. Enrollment continues in the KEYNOTE-B79 Phase 1b trial for CYAD-101. Preliminary data from the trial are expected in the second half of 2022; In addition, the KEYNOTE-B79 study will be the subject of a presentation at the upcoming American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium being held from January 20-22, 2022. Investigational New Drug (IND)-enabling studies continue for CYAD-203. Submission of the IND application for CYAD-203 is expected in the second half of 2022.

© S&P Capital IQ 2022
05/17Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference
05/06Celyad Oncology SA Reports Earnings Results for the First Quarter Ended March 31, 2022
05/05CELYAD ONCOLOGY SA : 1st quarter results
05/05CELYAD ONCOLOGY SA : Proxy Statments
04/01CELYAD ONCOLOGY SA : Ordinary general shareholder meeting
03/25TRANSCRIPT : Celyad Oncology SA, 2021 Earnings Call, Mar 25, 2022
03/25CELYAD ONCOLOGY : Reports Full Year 2021 Financial Results and Recent Business Highlights ..
03/25CELYAD ONCOLOGY : Letter to Shareholders – March 2022
03/24Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2021
03/24Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights
More news
Analyst Recommendations on CELYAD ONCOLOGY SA
More recommendations
Sales 2022 7,27 M 7,67 M 7,67 M
Net income 2022 -34,7 M -36,6 M -36,6 M
Net cash 2022 9,67 M 10,2 M 10,2 M
P/E ratio 2022 -1,35x
Yield 2022 -
Capitalization 41,1 M 43,4 M 43,4 M
EV / Sales 2022 4,33x
Capi. / Sales 2023 4,66x
Nbr of Employees 98
Free-Float 60,2%
Duration : Period :
Celyad Oncology SA Technical Analysis Chart | CYAD | BE0974260896 | MarketScreener
Technical analysis trends CELYAD ONCOLOGY SA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,82 €
Average target price 11,00 €
Spread / Average Target 504%
EPS Revisions
Managers and Directors
Filippo Joseph Petti Director, Chief Executive & Financial Officer
Michel E. Lussier Chairman
Frederic Lehmann VP-Clinical Development & Medical Affairs
David Gilham Chief Scientific Officer
Peggy Sotiropoulou Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704